Phoenix Biosciences, Inc. Issued United States Patent for the Clinical Development of PBS119 For HIV/AIDS; New patent marks first step towards clinical studies

Phoenix Biosciences, Inc. Issued United States Patent for the Clinical Development of PBS119 For HIV/AIDS; New patent marks first step towards clinical studies

Business Wire - June 28, 2004

HOLLYWOOD, Fla.-- Phoenix Biosciences, Inc. (PBS), focused on developing affordable, non-toxic treatments for HIV/AIDS, announced today that the U.S. Patent and trademark office has granted PBS Patent Number 6,734,192. This patent was provided to Phoenix Biosciences, Inc., for their novel immunological method, which claims to reduce HIV activity.

"The approval of this patent is an important step for our development team to move forward with clinical studies of PBS119," said Dr. Robert Keller, Chairman and CEO of Phoenix Biosciences. "Phoenix Biosciences will now aggressively pursue the execution of Phase I/II clinical trials, which will focus on patients experiencing drug resistance."

PBS119 utilizes a novel clinical approach being investigated for safety and clinical efficacy for advanced stage HIV/AIDS disease. PBS119 has been identified as having immune rebuilding potential and antiviral activity. Phoenix Biosciences is currently pursuing initial human studies that will be conducted in compliance with federal clinical trial guidelines.

Dr. Keller has been in clinical practice for the treatment of HIV/AIDS for 25 years and is certified and also sits on the Board of Governors for the Florida Chapter of the American Academy of HIV medicine. In addition, the Consumers' Research Council of America has voted Keller as one of America's top physicians in the field of immunology.

About Phoenix Biosciences, Inc.

Phoenix Biosciences, Inc., an emerging biotech company focused on developing affordable, non-toxic treatments for HIV/AIDS, Hepatitis and viral infections. The company's current lead research compound PBS119 indicates to possess broad spectrum HIV specific qualities. With headquarters in Hollywood, Florida, Phoenix Biosciences, Inc. is a privately-held biotech company. For more information about Phoenix Biosciences, Inc., please email pbs@robkellermd.org or visit www.robkellermd.org.

CONTACT: KNB Communications, LLC

Patricia Sugrue

Tel: 212.505.2441

Fax: 212.505.0698

psugrue@knbpr.com

SOURCE: Phoenix Biosciences, Inc.

040628
BW040617

Copyright © 2004 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .